Androgenetic alopecia. Androgenic alopecia, unspecified
Conditions
Interventions
Intervention 1: Intervention group 1: Oral consumption of finasteride 1 mg daily for 25 weeks. Intervention 2: Intervention group 2: Oral consumption of dutasteride 0.5 mg daily for 25 weeks.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Male patients diagnosed with moderate to severe androgenetic alopecia (grade 3, 4, 5 Hamilton-norwood scale) Do not have any of the followings (Non-inclusion criteria): any serious systemic disease, psoriasis or lichen planus; other types of alopecia (including anagen effluvium, telogen effluvium and scarring alopecia); any andrological condition known to affect semen parameters and male fertility (including varicocele, cryptorchidism, testicular cancer, testicular trauma, orchitis, urinary tract infection; previous chemotherapy or radiotherapy); history of hair transplant; history of breast cancer or male infertility in first degree relatives. Patients who have not received any treatment for alopecia in the past three months
Exclusion criteria
Exclusion criteria: Serum levels of prostate specific antigen (PSA) greater than 2 ng/ml Abnormal liver function tests (except chronic stable hepatitis B and C)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of hair follicles. Timepoint: Obtaining standard photographic pictures before the intervention and 25 weeks after the intervention. Method of measurement: A 7-point questionnaire developed by a physician based on the comparison of standard photographic pictures (checking the thickness and number of hairs).;Hair growth rate. Timepoint: perform scalp dermoscopy before the intervention and 25 weeks after the intervention. Method of measurement: A 7-point questionnaire developed by a physician based on the comparison of phototrichograms (checking the thickness and number of hairs).;Patient satisfaction score. Timepoint: before the intervention and 25 weeks after the intervention which is the end of the study. Method of measurement: ????? ?????? ????. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sexual dysfunction. Timepoint: Before the intervention and 25 weeks after the intervention which is the end of the study. Method of measurement: Interview with the patient.;Erectile dysfunction. Timepoint: Before the intervention and 25 weeks after the intervention which is the end of the study. Method of measurement: Interview with the patient.;Any side effects following consumption of finasteride and dutasteride. Timepoint: Every 3 months. Method of measurement: Interview with the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNazila Poostiyan
Esfahan University of Medical Sciences
Outcome results
None listed